Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PODOMOUNT-Basket
NCT07355296Phase 2Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2026
- Primary completion
- Jan 2028
- Countries
- 32
01
Overview
A Phase 2 trial of apecotrep in focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), Alport syndrome, primary membranous nephropathy (PMN), sponsored by Boehringer Ingelheim. Started Mar 2026; status: recruiting.
02
Drugs
apecotrep
03
Conditions
focal segmental glomerulosclerosis (FSGS)minimal change disease (MCD)Alport syndromeprimary membranous nephropathy (PMN)
Beyond the preview
Go deeper on NCT07355296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07355296.